A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

MLA

Magenau, John, et al. “A Phase 2 Trial of CD24Fc for Prevention of Graft-versus-Host Disease.” Blood, vol. 143, no. 1, Jan. 2024, pp. 21–31. EBSCOhost, https://doi.org/10.1182/blood.2023020250.

APA

Magenau, J., Jaglowski, S., Uberti, J., Farag, S. S., Riwes, M. M., Pawarode, A., Anand, S., Ghosh, M., Maciejewski, J., Braun, T., Devenport, M., Lu, S., Banerjee, B., DaSilva, C., Devine, S., Zhang, M.-J., Burns, L. J., Liu, Y., Zheng, P., & Reddy, P. (2024). A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood, 143(1), 21–31. https://doi.org/10.1182/blood.2023020250

Chicago

Magenau, John, Samantha Jaglowski, Joseph Uberti, Sherif S. Farag, Mary Mansour Riwes, Attaphol Pawarode, Sarah Anand, et al. 2024. “A Phase 2 Trial of CD24Fc for Prevention of Graft-versus-Host Disease.” Blood 143 (1): 21–31. doi:10.1182/blood.2023020250.